Predicting T cell epitopes useful for vaccination

US11156617B2 · kind B2 · utility

Assignees

• BIONTECH RNA PHARMACEUTICALS GMBH · DE
• TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz · DE

Inventors

• Ugur Sahin · Mainz, DE
• Martin Löwer · Bodenheim, DE
• Arbel David Tadmor · Bodenheim, DE
• Sebastian Boegel · Obermoschel, DE
• Barbara Schrörs · Mainz, DE
• Mathias Vormehr · Mainz, DE
• Sebastian Kreiter · Mainz, DE

Key dates

• Filing date: Feb 9, 2016
• Grant date: Oct 26, 2021
• Expiry date: Jan 20, 2037

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2500/04
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present invention relates to methods for predicting T cell epitopes useful for vaccination. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic and, in particular, useful for vaccination, or for predicting which of such modifications are most immunogenic and, in particular, most useful for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and thus, in the context of personalized cancer vaccines.